Block-Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125-mediated immunosuppression

por Grasso, Luigi, Kline, James Bradford, Nicolaides, Nicholas C.
Publicado 2022

Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement

por Kline, James Bradford, Kennedy, Rina P., Albone, Earl, Chao, Qimin, Fernando, Shawn, McDonough, Jennifer M., Rybinski, Katherine, Wang, Wenquan, Somers, Elizabeth B., Schweizer, Charles, Grasso, Luigi, Nicolaides, Nicholas C.
Publicado 2017